Name: | clopidogrel |
---|---|
PubChem Compound ID: | 10002188 |
Molecular formula: | C16H18ClNO6S2 |
Molecular weight: | 419.902 g/mol |
Name: | clopidogrel |
---|---|
Name (isomeric): | DB00758 |
Drug Type: | small molecule |
Brand: | Clopidogrel [Ban:Inn], Plavix, Clopidogrel sulfate |
Category: | Fibrinolytic Agents, Platelet Aggregation Inhibitors, Antiplatelet Agents |
CAS number: | 113665-84-2 |
Indication: | For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease |
---|---|
Pharmacology: | Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to reduce atherosclerotic events such as myocardial infarction, stroke, and vascular death in patients who have had a recent stroke, recent MI, or have established peripheral vascular disease. |
Mechanism of Action: |
The active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. he drug specifica...
show more » |
Absorption: | Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites. Bioavailability has not been found to be affected by food. |
Protein binding: | 98% |
Biotransformation: | Hepatic, extensive and rapid, by hydrolysis to the main circulating metabolite, a carboxylic acid derivative, which accounts for approximately 85% of the circulating drug-related compounds. A glucuronic acid derivative of the carboxylic acid derivative has also been found in plasma and urine. Neither the parent compound nor the carboxylic acid derivative has a platelet inhibiting effect. |
Route of elimination: | Following an oral dose of 14C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing. |
Half Life: | Carboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days. |
Toxicity: | Symptoms of acute toxicity include vomiting (in baboons), prostration, difficult breathing, and gastrointestinal hemorrhage. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|